Key facts
- This page summarizes Adrian Haigh's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 May 2024, 17:05.
Adrian Haigh - 16 May 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)
- Reporting relationship
- CHIEF OPERATING OFFICER
- Issuer ticker
- FENC
- Reported as of
- 16 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 May 2024, 17:05:25 UTC
- Prior SEC filing
- 22 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adrian Haigh
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Adrian Haigh filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 21 May 2024.
Change
- Previous filing in this sequence was filed on 22 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FENC
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 410,246
- Date
- 16 May 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 50,000
- Exercise price
- $7.12
- Footnotes
- F1, F2
FENC
transaction
Derivative
Restricted Shste Unit
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- +6.1%
- Price
- $0.000000
- Shares after
- 435,246
- Date
- 16 May 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 25,000
- Exercise price
- $0.000000
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On May 16, 2024, Adrian Haigh was granted incentive stock options to purchase 50,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan.
Footnote F2
2. One-third of the shares subject to this option may be exercised as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this option may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this option shall be vested.
Footnote F3
On May 16, 2024, Adrina Haigh was awarded restricted share units to acquire 25,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan
Footnote F4
One-third of the shares subject to this award shall be released from restriction as of May 16, 2025 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction..